Alnylam Pharmaceuticals, Inc. (ALNY): Price and Financial Metrics


Alnylam Pharmaceuticals, Inc. (ALNY): $129.31

4.44 (+3.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALNY POWR Grades


  • ALNY scores best on the Value dimension, with a Value rank ahead of 59.74% of US stocks.
  • ALNY's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • ALNY ranks lowest in Momentum; there it ranks in the 12th percentile.

ALNY Stock Summary

  • With a one year PEG ratio of 292.4, Alnylam Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.42% of US stocks.
  • ALNY's price/sales ratio is 23.74; that's higher than the P/S ratio of 93.73% of US stocks.
  • With a year-over-year growth in debt of 91.41%, Alnylam Pharmaceuticals Inc's debt growth rate surpasses 89.11% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Alnylam Pharmaceuticals Inc, a group of peers worth examining would be FOLD, BGNE, PXLW, CDXS, and EA.
  • ALNY's SEC filings can be seen here. And to visit Alnylam Pharmaceuticals Inc's official web site, go to www.alnylam.com.

ALNY Valuation Summary

  • ALNY's price/earnings ratio is -27; this is 173.97% lower than that of the median Healthcare stock.
  • ALNY's EV/EBIT ratio has moved down 28.4 over the prior 210 months.
  • Over the past 210 months, ALNY's price/sales ratio has gone down 400.7.

Below are key valuation metrics over time for ALNY.

Stock Date P/S P/B P/E EV/EBIT
ALNY 2021-08-31 34.8 28.1 -27.0 -31.5
ALNY 2021-08-30 35.2 28.3 -27.3 -31.8
ALNY 2021-08-27 35.3 28.4 -27.3 -31.9
ALNY 2021-08-26 35.0 28.2 -27.1 -31.6
ALNY 2021-08-25 35.4 28.5 -27.5 -32.0
ALNY 2021-08-24 34.9 28.1 -27.1 -31.6

ALNY Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -36.34%.
  • Its year over year revenue growth rate is now at 99.68%.
  • Its 3 year net cashflow from operations growth rate is now at -141.56%.
Over the past 70 months, ALNY's revenue has gone up $814,382,000.

The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 844.287 -641.693 -852.824
2021-09-30 749.314 -614.696 -837.904
2021-06-30 687.534 -590.986 -886.681
2021-03-31 570.943 -604.46 -876.351
2020-12-31 492.853 -614.961 -858.281
2020-09-30 400.972 -687.797 -890.926

ALNY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
  • ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
  • QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.

The table below shows ALNY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.220 0.833 -0.249
2021-06-30 0.204 0.833 -0.267
2021-03-31 0.171 0.832 -0.272
2020-12-31 0.159 0.842 -0.308
2020-09-30 0.141 0.832 -0.372
2020-06-30 0.130 0.853 -0.416

ALNY Price Target

For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $184.16 Average Broker Recommendation 1.64 (Moderate Buy)

ALNY Stock Price Chart Interactive Chart >

Price chart for ALNY

ALNY Price/Volume Stats

Current price $129.31 52-week high $212.00
Prev. close $124.87 52-week low $117.58
Day low $125.66 Volume 721,564
Day high $130.10 Avg. volume 833,083
50-day MA $153.46 Dividend yield N/A
200-day MA $171.13 Market Cap 15.62B

Alnylam Pharmaceuticals, Inc. (ALNY) Company Bio


Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company was founded in 2002 and is based in Cambridge, Massachusetts.


ALNY Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNY Latest Social Stream


Loading social stream, please wait...

View Full ALNY Social Stream

Latest ALNY News From Around the Web

Below are the latest news stories about Alnylam Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 15, 2022

Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected To Breakeven In The Medium-Term

We feel now is a pretty good time to analyse Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) business as it appears the...

Yahoo | February 15, 2022

BMO Capital Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

BMO Capital analyst Gary Nachman maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $175.00. The company's shares closed last Friday at $148.79. According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of -4.4% and a 42.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Horizon Therapeutics. Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $210.53, implying a 41.0% upside from current levels.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Cigna (CI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $200.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Brian Anderson on TipRanks | February 11, 2022

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Dyadic International (DYAI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Dyadic International (DYAI – Research Report) and SCYNEXIS (SCYX – Research Report). Alnylam Pharma (ALNY) In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company's shares closed last Thursday at $150.86. According to TipRanks.

Christine Brown on TipRanks | February 11, 2022

Read More 'ALNY' Stories Here

ALNY Price Returns

1-mo N/A
3-mo -15.64%
6-mo -27.75%
1-year -4.84%
3-year 91.46%
5-year 81.90%
YTD -23.75%
2021 30.48%
2020 12.85%
2019 57.96%
2018 -42.61%
2017 239.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7527 seconds.